Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egle

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Frontiers in Oncology|February 15, 2021
The Effect of <i>SF3B1</i> Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in CancerAlexander C Leeksma, Ingrid A M Derks, M Haidar Kasem, et al.
American Journal of Hematology|December 30, 2014
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2bNicole C C Them, Klaudia Bagienski, Tiina Berg, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
Antimicrobial Resistance and Infection Control|December 21, 2021
Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19Simon Matoori, Daniel R Kuritzkes, Yonggeng Goh, et al.
Cancer Cell|January 19, 2013
Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivoGloria Lutzny, Thomas Kocher, Marc Schmidt-Supprian, et al.
Leukemia|June 25, 2021
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendationsWilliam G Wierda, Andrew Rawstron, Florence Cymbalista, et al.
Ejhaem|June 19, 2024
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 studyHeinz Ludwig, Thomas Melchardt, Ilvy Schweitzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2025
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz, et al.
AIDS (London, England)|July 7, 2026
CD4+ cell count trends after common cancers in people with HIV: a multicohort collaborationAlisa Timiryasova, Lauren Greenberg, Pere Domingo, et al.
American Journal of Hematology|March 1, 2024
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myelomaHeinz Ludwig, Thomas Melchardt, Siegfried Sormann, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Frontiers in Oncology|February 15, 2021
The Effect of <i>SF3B1</i> Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in CancerAlexander C Leeksma, Ingrid A M Derks, M Haidar Kasem, et al.
American Journal of Hematology|December 30, 2014
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2bNicole C C Them, Klaudia Bagienski, Tiina Berg, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
Antimicrobial Resistance and Infection Control|December 21, 2021
Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19Simon Matoori, Daniel R Kuritzkes, Yonggeng Goh, et al.
Cancer Cell|January 19, 2013
Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivoGloria Lutzny, Thomas Kocher, Marc Schmidt-Supprian, et al.
Leukemia|June 25, 2021
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendationsWilliam G Wierda, Andrew Rawstron, Florence Cymbalista, et al.
Ejhaem|June 19, 2024
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 studyHeinz Ludwig, Thomas Melchardt, Ilvy Schweitzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2025
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz, et al.
AIDS (London, England)|July 7, 2026
CD4+ cell count trends after common cancers in people with HIV: a multicohort collaborationAlisa Timiryasova, Lauren Greenberg, Pere Domingo, et al.
American Journal of Hematology|March 1, 2024
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myelomaHeinz Ludwig, Thomas Melchardt, Siegfried Sormann, et al.
Pageof 11